Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma

Xiaobin Fu†, Tingting Li†, Yaqing Dai‡ and Jiancheng Li‡*

Abstract

Background: The aim of this study was to assess the prognostic significance of preoperative systemic inflammation score (SIS) on patients with esophageal squamous cell carcinoma (ESCC).

Methods: A total of 357 ESCC patients who accepted radical esophagectomy between January 2008 and December 2009 at our institution were recruited in the analysis. The cut-off finder application was used to calculate the optimal cutoff values. The Chi-squared test or Fisher’s exact test were used to analyze categorical variables. Overall survival (OS) was calculated using the Kaplan-Meier method and the log-rank test. Multivariate analysis was calculated using Cox regression analysis model. A model combining SIS was created and its performance was evaluated using the Akaike information criterion (AIC) and concordance index (C-index).

Results: The median follow-up time was 58 months (range, 1–84 months). The 5-year OS rate was 50% (95% CI, 49.94–50.06%). The optimal cut-off values for preoperative neutrophil to lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and serum albumin (Alb) were 2.27, 3.79 and 36.55, respectively. Univariate analyses revealed that gender (P = 0.047), T stage (P < 0.001), N stage (P < 0.001), vascular invasion (P < 0.001), tumor location (P = 0.018), tumor length (P < 0.001), NLR (P = 0.006), LMR (P = 0.007), serum Alb (P = 0.001), and SIS (P < 0.001) were significantly associated with OS. Independent prognostic factors for OS were T stage, N stage, tumor location, tumor length, and SIS. However, NLR was not an independent prognostic factor in multivariate analysis. The model combining SIS had smaller AIC and higher C-index compared to the model without SIS, which suggesting that the adding the SIS to the multivariate model increasing the predictive accuracy of the OS in the ESCC patients treated with radical esophagectomy and 3-field lymphadenectomy (3-FL).

Conclusions: SIS may treat as a novel prognostic factor than NLR for ESCC patients who underwent radical esophagectomy and 3-FL. However, Larger-scale studies are needed to validate these findings.

Keywords: Esophageal squamous cell carcinoma, Systemic inflammation score, Neutrophil to lymphocyte ratio, Prognosis
Background

There are huge differences between the United States (US) and China in the incidence and pathologic type of esophageal carcinoma (EC). Unlike the US, EC is one of the prevalent malignant carcinoma in China with high incidence and mortality and squamous cell carcinoma is the main pathologic type which accounted for 90% of EC. The crude incidence rate of esophageal carcinoma in 2014 was 12.17/100,000, which represented 18.85% of all estimated cancer cases [1, 2]. With the significant development in treatment methods for esophageal squamous cell carcinoma (ESCC), the average survival rate increased by 2.9% per calendar period from 2003 to 05 to 2012–15. However, the prognosis of ESCC remained poor and the 5-year survival rate was merely 30.2% [3].

Previous in vitro and in vivo studies revealed that the degree of systemic inflammatory response significantly affected the outcomes in various solid carcinomas including the stomach, kidney, and esophageal carcinoma by increasing the probability for primary tumor invasion, distant metastasis, and immune tolerance [4–7]. Based on the relationship between inflammatory response and overall survival, the inflammation-based factors including the inflammation score (SIS), combined the pretreatment albumin levels and lymphocyte to monocyte (LMR), and prognostic nutritional index (PNI) have been showed to have prognostic value in cancer patients [8–10].

Among the inflammation-based factors mentioned above, NLR was widely reported as a timesaving, economical, repeatable and routine inflammation-based prognostic indicators were widely used to monitor the degree of systemic inflammatory response for various solid carcinoma and predict the patient prognosis in the recent studies [11–14]. However, there is no widely accepted optimal cutoff value for NLR and no established scoring system that combines the inflammation indicators to predict the prognosis of cancer patients. Recently, the systemic inflammation score (SIS), combined the pretreatment albumin levels and lymphocyte to monocyte (LMR), was reported as a novel prognostic indicator for gastric carcinoma and clear cell renal carcinoma [15, 16]. However, the studies about the predictive value of systemic inflammation score (SIS) in esophageal carcinoma are few, and no studies regarding the prognostic value of preoperative SIS compared with NLR in ESCC treated with radical esophagectomy and 3-field lymphadenectomy (3-FL).

Thus, the aim of this study was to assess the predictive value of preoperative SIS in ESCC patients treated with the radical esophagectomy and 3-FL.

Methods

Patients

This study was approved by the Ethics Committee of the Fujian Provincial Cancer hospital (NO. KT2018–014–01). 357 consecutive ESCC cases who meet the following criteria were recruited in this retrospective study, (a) the Karnofsky score ≥ 80 points, (b) pathologically confirmed as ESCC, (c) the patients received radical esophagectomy and 3-FL with at least 15 lymph nodes resected, (e) without a history of malignant disease, and (f) the patients received blood routine test and biochemical examination 7 days prior to surgery.

Surgical strategy

All the ESCC patients included in the study received radical esophagectomy by total thoracotomy on the left side and intrathoracic gastric reconstruction. All the patients underwent the 3-field lymphadenectomy (neck, mediastinum and abdomen) which including the supraclavicular, pararvanygeal, paratracheal, paratranchial, paraesophageal, subcarinal, diaphragmatic, and paracardiac lymph nodes, as well as lymph nodes located along lesser gastric curvature, left gastric artery lymph nodes.

Radiation and chemotherapy

In this study, 214 ESCC patients received intensity-modulated radiation therapy (IMRT) and chemotherapy. The cervical, thoracic and abdominal parts were fixed using plastic sheet or vacuum pad. Imaging data were collected from prior computed tomography (CT) simulation scan and transmitted to radiation therapy treatment planning system (Pinnacle, Philips Radiation Oncology System, USA) to delineate the tumor area and the organs at risk according to the criteria of tumor sketching of the National Comprehensive Cancer Network (NCCN). Additional parameters included prescribed dose of 50–66 Gy, median dose of 60 Gy, Bi-lung V20 ≤ 20%, an average bi-lung dose of ≤20 Gy, a bi-lung V5 of < 50%, a heart V30 of ≤30%, and a maximum dose to the spinal cord of < 45 Gy. The chemotherapy regimens used in ESCC patients was as followed, docetaxel 135–175 mg/m2 D1 + cisplatin 80 mg/m2 D2.

Definition of the NLR, LMR and SIS

Data of the pretreatment absolute blood cell counts were collected from the previous blood routine test records in Fujian Provincial Cancer Hospital. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The LMR was defined as the absolute lymphocyte count divided by the monocyte count. SIS defined based on the combination of the preoperative serum Alb and LMR was as followed, a) patients with both increased LMR and increased serum Alb were defined as a score of 1, b) patients with either increased LMR or increased serum Alb were defined as a score of 2 [15, 16].
Pathological staging
All the ESCC patients were performed the pathological TNM staging based on the pathological diagnosis by the experienced oncologist according to the 8th edition TNM stage issued by American Joint Committee on Cancer (AJCC). For the T1a ESCC with tumor cell G1, the patients were classified as stage Ia. For the T1a ESCC with tumor G2/3, T2 ESCC with tumor cell G1 and T1b ESCC, the patients were classified as stage Ib. For the T2 ESCC with tumor cell G2/3, the T3 ESCC with tumor cell G1 and T3 ESCC with tumor cell G2/3 located in the lower third, the patients were classified as stage IIa. For the T3 ESCC with tumor cell G2/3 located in the middle and upper third and the T1 N1, the patients were classified as stage IIb. For the T4 N1 and T2 N1 ESCC, the patients were classified as stage IIIa. For the T4 N2, T3 N1−2 and T4a N0−1 ESCC, the patients were classified as stage IIIb. For the T4b N0−3 and T1−4 N3 ESCC, the patients were classified as Iva.

Follow-up
A regular follow-up examination was conducted every 3 months the first year, every 6 months the next 2 years, and once per year thereafter. The routine examination included physical examination, routine blood test, biochemical examination, the thoracic and upper abdominal CT scan, barium meal radiograph. December 2014 was the last censoring date for evaluating survival time. Survival time was defined as the interval between the date of surgery to the death or last follow-up.

Statistical analysis
All recorded data were calculated by SPSS (version 19.0, SPSS Inc., Chicago, IL, USA) and the statistical software “R” (version 2.11.1, the R Foundation for statistical computing). The cutoff finder application was performed to calculate the optimal cutoff value. The Chi-squared test or Fisher’s exact test was used to compare the differences of pathological stage factors in the patients grouped by NLR and SIS. The survival rate was calculated using the Kaplan-Meier method, and a log-rank test was used to assess the survival differences between groups. Cox proportional hazards regression analysis was performed to identify independent factors that were correlated with the patients’ overall survival. The Akaike information criterion (AIC) was used to identify a superior multivariate prediction model. The predictive accuracy of the two models was also identified by the concordance index (C-index), which ranged from 0 to 1. The corresponding interval (CI) was calculated by bootstrapping and p-value of C-index was calculated according to assume asymptotic normality. The larger C-index value revealed a better predictive accuracy. All tests were two-sided, and a P value < 0.05 was considered statistically significant.

Result
Patients’ characteristics
A total of 357 patients (279 males and 78 females) meet the inclusion criteria were enrolled (Table 1). The median age was 57 years (range, 34 to 77y). The patients for tumor located in upper third (UE), middle third (ME), and lower third (LE) were 60 (16.8%), 260 (72.8%), and 37 (10.4%), respectively. The tumor cell G1, G2, and G3 were 54 (15.1%), 258(72.3%), and 45 (12.6%), respectively. The patients for stage Ib, Iia, Iib, IIIa, IIIb, IVa were 29(8.1%), 71(19.8%), 52(14.6%), 23(6.4%), 126(35.2%), and 56(15.7%) respectively. The association of the NLR and SIS are

Table 1 Patients’ characteristics for 357 ESCC patients

| Characteristics          | Number of patients (%) |
|--------------------------|------------------------|
| Gender                   |                        |
| Male                     | 279 (78.2)             |
| Female                   | 78 (21.8)              |
| Age (years)              |                        |
| ≤ 65                     | 276 (77.3)             |
| > 65                     | 81 (22.7)              |
| Vascular invasion        |                        |
| Yes                      | 312 (87.4)             |
| No                       | 45 (12.6)              |
| Tumor cell differentiation|                       |
| G1                       | 54 (15.1)              |
| G2                       | 258 (72.3)             |
| G3                       | 45 (12.6)              |
| Tumor location           |                        |
| Upper third              | 60 (16.8)              |
| Middle third             | 260 (72.8)             |
| Lower third              | 37 (10.4)              |
| T stage                  |                        |
| T1                       | 40 (11.2)              |
| T2                       | 71 (19.9)              |
| T3                       | 209 (58.5)             |
| T4                       | 37 (10.4)              |
| N stage                  |                        |
| N0                       | 155 (43.4)             |
| N1−3                     | 202 (56.6)             |
| Pathological stage       |                        |
| I                        | 29 (8.1)               |
| II                       | 123 (34.5)             |
| III                      | 149 (41.7)             |
| IVa                      | 56 (15.7)              |
| Adjuvant therapy         |                        |
| Yes                      | 214 (60)               |
| No                       | 143 (40)               |
showed in the Table 2. Our study showed that high NLR was associated with male sex \((P = 0.003)\), tumor length \((< 0.001)\), and \(T\) stage \((P = 0.002)\). The high SIS was associated with increased tumor length \((P = 0.004)\) (Additional file 1).

**ROC curve for prediction**

For NLR, the area under the curve (AUC) was 0.566 (95% CI 0.507–0.626). The optimal cutoff value was 2.27. The sensitivity and specificity were 0.431 and 0.71. For LMR, the area under the curve (AUC) was 0.576 (95% CI 0.517–0.636). The optimal cutoff value was 3.94. The sensitivity and specificity were 0.491 and 0.638. For serum Alb, the AUC was 0.578 (95% CI 0.518–0.637). The optimal cutoff value, sensitivity, and specificity were 36.55, 0.746, and 0.404. ROC curves of NLR, LMR, and Alb are shown in the Fig. 1a, b, and c.

**Table 2** ESCC Patients’ clinicopathological characteristics according to NLR and SIS

| Characteristics                  | NLR ≤ 2.27 | NLR > 2.27 | \(P\) | SIS groups |
|----------------------------------|------------|------------|-------|------------|
|                                  | \(N = 228\) | \(N = 129\) |       | \(N = 119\) | \(N = 148\) | \(N = 90\) | \(P\) |
| Gender                           |            |            | 0.003 |            |            |            | < 0.001 |
| Male                             | 167        | 112        |       | 71         | 128        | 80        |
| Female                           | 61         | 17         |       | 48         | 20         | 10        |
| Age                              |            |            | 0.874 |            |            | 0.087     |        |
| ≤ 65 years old                   | 177        | 99         |       | 95         | 119        | 62        |
| >65 years old                    | 51         | 30         |       | 24         | 29         | 28        |
| Vascular Invasion\(a\)           |            |            | 0.453 |            |            | 0.944     |        |
| No                               | 197        | 115        |       | 103        | 130        | 79        |
| Yes                              | 31         | 14         |       | 16         | 18         | 11        |
| Tumor cell differentiation\(a\)  |            |            | 0.561 |            |            | 0.412     |        |
| G1                               | 31         | 23         |       | 14         | 21         | 15        |
| G2                               | 168        | 90         |       | 90         | 109        | 18        |
| G3                               | 29         | 16         |       | 15         | 18         | 12        |
| Tumor location\(a\)              |            |            | 0.728 |            |            | 0.324     |        |
| Upper                            | 41         | 16         |       | 21         | 26         | 7         |
| Middle                           | 164        | 96         |       | 91         | 105        | 17        |
| Lower                            | 23         | 14         |       | 7          | 64         | 13        |
| Tumor length                     |            |            | < 0.001|            |            | 0.004     |        |
| ≤ 5 cm                           | 167        | 69         |       | 91         | 98         | 49        |
| > 5 cm                           | 61         | 60         |       | 28         | 50         | 41        |
| T stage                          |            |            | 0.002 |            |            | 0.102     |        |
| T1                               | 33         | 7          |       | 18         | 14         | 8         |
| T2                               | 53         | 18         |       | 26         | 34         | 11        |
| T3                               | 124        | 85         |       | 60         | 89         | 60        |
| T4                               | 18         | 19         |       | 15         | 11         | 11        |
| N stage                          |            |            | 0.266 |            |            | 0.161     |        |
| N0                               | 104        | 51         |       | 58         | 65         | 32        |
| N1–3                             | 124        | 78         |       | 61         | 83         | 58        |
| Stage                            |            |            | 0.109 |            |            | 0.117     |        |
| I                                | 24         | 5          |       | 14         | 12         | 3         |
| II                               | 81         | 24         |       | 43         | 51         | 29        |
| III                              | 90         | 59         |       | 49         | 61         | 39        |
| IVa                              | 33         | 23         |       | 13         | 24         | 19        |

\(a\) While \(N \geq 40\) and \(1 \leq \text{theoretical frequency}(T) < 5\), the Fisher exact test was used to compare the influencing factors.
with both LMR > 3.94 and serum Alb > 36.55 were defined as a score of 0, b) patients with either LMR > 3.94 or serum Alb > 36.55 were defined as a score of 1, c) patients with both serum Alb ≤ 36.55 and LMR ≤ 3.94 were defined as a score of 2.

Survival for the whole cohort and prognostic impact of the SIS and NLR

The median follow-up time was 58 months (ranging: 1–84 months). Among the 357 ESCC cases, the 1-year, 3-year, and 5-year survival rate were 82% (95% CI, 81.96–82.04), 61% (95% CI, 60.96–61.04), and 50% (95% CI, 49.94–50.06), respectively. In our cohort, for NLR ≤ 2.27 (n = 228) and NLR > 2.27 (n = 129), the 5-year survival rate were 56% (95% CI, 59.94–56.06%) and 40% (95% CI, 39.92–40.08%), respectively. For SIS = 0 (n = 64), SIS = 1 (n = 60), and SIS = 2 (n = 20), the 5-year survival rate were 61% (95% CI, 60.92–61.08%), 50% (95% CI, 49.92–50.08%) and, 35% (95% CI, 34.9–35.1%) respectively. Kaplan–Meier analysis demonstrated that the association of SIS and NLR with OS. High SIS and low NLR were associated with inferior OS (for the SIS, P = 0.001; for the NLR, P = 0.006). Kaplan–Meier curves of OS based on pretreatment SIS and NLR are shown in Fig. 2a and b.

Prognostic factors affecting OS in the whole cohort

Univariate analysis demonstrated that gender (P = 0.047), T stage (P < 0.001), N stage (P < 0.001), vascular invasion (P < 0.001), tumor location (P = 0.018), adjuvant CRT (P = 0.036), tumor length (P < 0.001), NLR (P = 0.006), and SIS (P < 0.001) were significant associated with OS of 357 ESCC patients. Multivariate analysis showed that T stage (P = 0.008), N stage (P < 0.001), tumor location (P = 0.025), tumor length (P = 0.002), and SIS (P = 0.029) were independent prognostic factors (Table 3).
Comparisons between the two multivariate models

The comparisons of multivariate models 1 (gender, age, T stage, N stage, vascular invasion, tumor cell differentiation, pathological stage, tumor length, and tumor location) and multivariate model 2 (gender, age, T stage, N stage, vascular invasion, tumor cell differentiation, pathological stage, tumor location, tumor length and SIS) assessed by the AIC, C-index, and likelihood ratio χ² score (Table 4). The AIC values in the multivariate model 1 and 2 were 1999.66 and 1999.53. The AIC value was smaller in the model 2, suggesting that combining SIS to the multivariate model enabled a superior prediction model for OS. Moreover, the C-index value in the multivariate model 1 and 2 were 0.715 (0.672–0.759) and 0.718 (0.675–0.762). The C-index increased slightly in the model 2, which suggesting that the adding the SIS to the multivariate model increasing the predictive accuracy of the OS in the ESCC patients treated with radical esophagectomy and 3-FL. However, the C-index of the model 2 was not significant differences compared to the model 1 (P = 0.91).

Discussion

Pretreatment prognostic factors including TNM staging, tumor grade, tumor location, and tumor burden might not comprehensively predict the prognosis of patients with ESCC. Accumulating studies have revealed that it is not just the influencing factors mentioned above affecting the ESCC patients’ prognosis. Moreover, inflammation-based factors and immunonutritional indicators such as the preoperative serum Alb and LMR, had found strongly prognostic value in our study. To our best knowledge, no studies regarding the prognostic value of preoperative SIS compared with NLR in ESCC. All the ESCC patients in our study underwent radical esophagectomy and 3-FL which eliminated the influence of surgical mode and pathological type on prognosis. We had shown that the ESCC patients with NLR ≤ 2.27, LMR > 3.94, Alb> 36.55 and low SIS had better OS. Moreover, the NLR, was not independent prognostic factors in multivariate analysis. The ESCC patients with low SIS had a significantly greater 5-year OS rate than those with high SIS (P < 0.001). SIS may treat as a novel prognostic factor than NLR for patients with ESCC who underwent radical esophagectomy and 3-FL.

Nowadays, a superior inflammation marker, the SIS, was reported to have the value in predicting the outcomes in the solid tumors such as gastric cancer, non-small cell lung cancer, cervical carcinoma et.al [15, 17, 18]. However, the studies focused on the relationship between the SIS and the ESCC patients’ outcome were rare. Jian-Xian Lin et.al [15], studied 1786 gastric cancer accepted the curative resection and revealed that the SIS was the independent prognostic factor in the gastric cancer patients. In that study, the SIS was established based on the combination the pretreatment serum Alb and LMR. Patient with low score (both elevated Alb and LMR) had a significant survival benefit compared with the patients with high score (both decreased Alb and LMR). In another study by Masaki Tomita et.al [17], who studied 341 non-small cell lung cancer and showed that SIS was a novel independent
| Variables              | Univariate |     | Multivariate |     |
|-----------------------|------------|-----|--------------|-----|
|                       | S-year OS  | *P* value (log-rank) | Hazard ratio | 95%CI | *P* value |
| Gender                |            | 0.047 |              |      |           |
| Male                  | 279        |     |              |      |           |
| Female                | 78         |     |              |      |           |
| Age (years)           |            | 0.159 |              |      |           |
| ≤ 65                  | 276        |     |              |      |           |
| > 65                  | 81         |     |              |      |           |
| T stage               |            | < 0.001 | 1.323 | 1.12–1.53 | 0.008 |
| T1                    | 40         |     |              |      |           |
| T2                    | 71         |     |              |      |           |
| T3                    | 209        |     |              |      |           |
| T4                    | 37         |     |              |      |           |
| N stage               |            | < 0.001 | 1.525 | 1.4–1.65 | < 0.001 |
| N0                    | 155        |     |              |      |           |
| N1                    | 87         |     |              |      |           |
| N2                    | 69         |     |              |      |           |
| N3                    | 46         |     |              |      |           |
| Vascular invasion     |            | <0.001 |      |      |           |
| No                    | 45         |     |              |      |           |
| Yes                   | 312        |     |              |      |           |
| Tumor cell            |            | 0.61 |              |      |           |
| G1                    | 54         |     |              |      |           |
| G2                    | 258        |     |              |      |           |
| G3                    | 45         |     |              |      |           |
| Tumor location        |            | 0.018 | 1.361 | 1.09–1.63 | 0.025 |
| Upper third           | 60         |     |              |      |           |
| Middle third          | 260        |     |              |      |           |
| Lower third           | 37         |     |              |      |           |
| Adjuvant CRT          |            | 0.036 |              |      |           |
| Yes                   | 214        |     |              |      |           |
| No                    | 143        |     |              |      |           |
| Tumor length          |            | < 0.001 | 1.609 | 1.31–1.9 | 0.002 |
| ≤ 5 cm                | 236        |     |              |      |           |
| > 5 cm                | 157        |     |              |      |           |
| SIS                   |            | < 0.001 | 1.24 | 1.05–1.43 | 0.029 |
| 0                     | 119        |     |              |      |           |
| 1                     | 148        |     |              |      |           |
| 2                     | 90         |     |              |      |           |
| NLR                   |            | 0.006 |              |      |           |
| ≤ 2.27                | 228        |     |              |      |           |
| >2.27                 | 129        |     |              |      |           |
prognostic factors in predicting the non-small cell lung cancer patients’ OS. In that study, the SIS was based on the combination the pretreatment serum C-reactive protein and Alb and showed that the patients with high SIS (C-reactive protein > 10 ng/L and Alb < 35 g/L) had adverse impact on the patients’ overall survival. Ru-ru Zheng et al. [18] performed the multivariate model analysis on 795 resectable cervical cancer showing that the SIS, combined the pretreatment serum Alb and PLR, was the independent prognostic factor. The patients with high SIS (Alb < 43.65 g/L and PLR ≥ 128.3) had a worse 5-year OS and 5-year disease free survival (DFS) than the patients with low SIS (Alb ≥ 43.65 g/L and PLR < 128.3). In addition to the solid cancer mentioned above, some studies also revealed the relationship between the LMR and outcomes in the esophageal carcinoma. Lihui Han et al. [19], studied the 206 ESCC patients underwent esophagectomy and found that the patients with low SIS (pretreatment serum Alb ≥ 43.1 g/L and LMR > 2.9) had a better 5-year disease free survival and overall survival than the patients with high SIS (pretreatment serum Alb < 43.1 g/L and LMR < 2.9). Similar to this study, the optimal cutoff value of Alb and LMR in our study were 36.55 g/L and 3.94. The patients with SIS = 0 (both Alb > 36.55 g/L and LMR > 3.94) had a better 5-year overall survival than the patients with SIS = 1(either Alb > 36.55 g/L or LMR > 3.94) and SIS = 2 (both Alb ≤ 36.55 g/L and LMR < 3.94) and the difference had significantly statistical difference. Moreover, the SIS was the independent prognostic factor by performing the multivariable code model analysis.

The underlying biological mechanism of SIS in impacting the patients’ prognosis might be determined by serum Alb and LMR. Some in vivo and in vitro studies verified that the low LMR and decreased serum albumin were significant correlation with the poor prognosis of the cancer patients [20–22]. Hypoalbuminemia represents the poor nutritional status and increased inflammatory degree which potentially exerting negative impact on the ESCC patients’ survival [23]. Moreover, hypoalbuminemia also decreases the agents such as cholesterol, fatty acid, et al transporting and free oxygen radicals scavenging, which have adversely outcomes on OS [24]. LMR consists of lymphocytes and monocytes. The biological reason of LMR might be demonstrated by the function of the lymphocytes and monocytes. The lymphocytes increased the antitumor reaction to suppress the tumor cell proliferation, migration, and angiogenesis. Thus, the patients with lymphopenia had poor survival outcomes in cancer patients [25]. In some other studies, the neutrophils and the monocytes promoted the tumor cell proliferation and modulated the tumor microenvironment to facilitate the angiogenesis, tumor invasion and metastases, and such that the cancer patients with low monocytes have poor OS [5]. Hu et al. [22], studied 218 ESCC patients and found that the patients with LMR > 2.57 had a better 5-year OS and disease-free survival than the patients with LMR < 2.57. Similar to this study, the optimal cutoff value of LMR in our study was 3.94. The patients with LMR > 3.94 had a better 5-year OS.

Except for the SIS mentioned above, a number of studies also demonstrated that pretreatment serum NLR, PLR, and PNI also significantly affected the outcomes of the OS of the colorectal, non-small cell lung cancer, gastric cancer and ESCC patients. Hao Duan et al. [26] studied 371 ESCC patients who underwent the esophagectomy and found that the pretreatment serum NLR > 3.0 was associated with the worse cancer-specific survival and recurrence-free survival. Keisuke Kosumi et al. [27], and Hiroshi Sato et al. [28] also had the similar findings. Similar to these studies, the optimal cutoff value for NLR calculated in our study was 2.27 and the patients with NLR > 2.27 had worse OS. In addition to the pretreatment serum NLR, the pretreatment serum PLR also played a crucial role in influencing the ESCC patients’ survival. A Meta-analysis by Deng [29] showed that the elevated pretreatment serum PLR was significantly associated with the poor outcomes of patients in esophageal carcinoma. However, the NLR was not an independent prognostic factors in our study. The NLR was not an independent prognostic factor in multivariate analysis. Only the SIS was the independent prognostic factors in this study. The SIS was superior to NLR in predicting the ESCC patients’ prognosis.

This study has a few limitations. Firstly, the sample size in this study is small cause the number of ESCC patients were limited. A larger amount of data is required to verify these results. Secondly, as a retrospective study, the analytical and selection biases was inevitable. Despite the limitations mentioned above, the study was the first to reveal the prognostic value of pretreatment SIS compared with ESCC patients treated with radical esophagectomy and 3-FL. SIS, as a timesaving, economical and reliable inflammation-based factors could be taken into consideration in the ESCC patients prognostic prediction and further treatment regimen selection.

**Table 4** Comparison of different prognostic models on 357 ESCC patients

| Model | Concordance Indices | AIC | Likelihood Ratio X² |
|-------|---------------------|-----|---------------------|
|       | C-index Bootstrap 95% Cl |     |                     |
| Model 1 | 0.715 0.672–0.759 | 1999.66 | 93.013          |
| Model 2 | 0.718 0.675–0.762 | 1999.53 | 95.146          |

**Conclusion**

Overall, SIS may treat as a novel prognostic factor than NLR for ESCC patients who underwent radical esophagectomy and 3-FL. Measurements of the SIS are
economical, timesaving, and reliable in the pretreatment work-up of ESCC patients in clinical practice. It will aid the oncologists in the individual treatment regimen selection. Larger-scale studies are warranted to validate these findings.

Additional file

Additional file 1: File SIS DATA information. The file included the data of the pretreatment NLR, LMR, Albumin and survival time of 357 ESCC patients. The gender, tumor location, tumor length, age, tumor cell differentiation, vascular invasion, T stage, N stage, clinical stage, NLR, LMR and albumin were divided into different subgroups according to the details list in the Tables 1 and 2. Survival time was defined as the interval between the date of surgery to the death or last follow-up. The survival group was divided into 2 subgroups (0 for survival and 1 for death). (XLSX 59 kb)

Acknowledgments

The authors thank all patients who participated in the present study.

Authors’ contributions

JL and XF participated in the design of the study, carried out the clinical data analysis and drafted the manuscript; TL and YD participated in the data collection; JL contribute with the clinical data analysis and involved in revising the manuscript; All authors read and approved the final manuscript.

Funding

This study was supported in part by grants from the Fujian Provincial Platform for Medical Laboratory Research and Key Laboratory for Tumor Individualized Active Immunity (Project Number: FYKFKT-2017015) in the design of the study and analysis, interpretation of data and in writing the manuscript.

Availability of data and materials

The data used to support the findings of this study are included with the article and supplementary files.

Ethics approval and consent to participate

This retrospective study was approved by Fujian Province Cancer Hospital Institutional Review Board (NO. KT2018-014-01). All patients provided written informed consent prior to treatment, and all information was anonymized prior to analysis.

Consent for publication

Not applicable.

Competing interests

The authors declare the submitted work was not carried out in the presence of any personal, professional or financial relationships that could potentially be construed as a conflict of interest.

Author details

Department of Radiation Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian, China. Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, 420 Fuma Road, Jian’an District, Fuzhou 350014, Fujian, China.

Received: 3 May 2019 Accepted: 15 July 2019
Published online: 22 July 2019

References

1.  Segel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:117–30. https://doi.org/10.3322/caac.21442.
2.  Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2018;30(1):1–12. https://doi.org/10.21147/j.issn.1000-9604.2018.01.01.
3.  Zeng H, Chen W, Zheng R, Zhang S, Ji J, Zou X, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–e67. https://doi.org/10.1016/s2214-109x(18)3017x.
4.  Durniu CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23(3):141–8. https://doi.org/10.1016/j.semcancer.2013.02.005.
5.  Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200–7. https://doi.org/10.1016/j.semcancer.2013.02.001.
6.  Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol. 2003;163(6):2221–32. https://doi.org/10.1016/s0002-9440(03)63580-8.
7.  Dakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. https://doi.org/10.1016/s1470-2045(14)70263-3.
8.  Schwiegler J, von Hoblen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg. 2010;97(1):92–7. https://doi.org/10.1002/bjs.6805.
9.  DeNardo DG, Johnsonn M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27(1):11–8. https://doi.org/10.1007/s10555-007-9100-0.
10.  McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40. https://doi.org/10.1016/j.ctrv.2012.08.003.
11.  Pergialiotis V, Oikonomou M, Damaskou V, Kalantzis D, Chrelias C, Tsantes AE, et al. Platelet to lymphocyte and neutrophil to lymphocyte ratio as predictive indices of endometrial carcinoma: findings from a retrospective series of patients and meta-analysis. J Gynecol Obstet Hum Reprod. 2018. https://doi.org/10.1016/j.jogoh.2018.08.016.
12.  Chen L, Zeng H, Yang J, Lu Y, Zhang D, Wang J, et al. Survival and prognostic analysis of preoperative inflammatory markers in patients undergoing surgical resection for laryngeal squamous cell carcinoma. BMC Cancer. 2018;18(1):816. https://doi.org/10.1186/s12885-018-4730-x.
13.  Nakamura K, Nakayama K, Tatsumi N, Minamoto T, Ishibashi T, Occhini K, et al. Prognostic significance of pre-treatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in non-surgically treated uterine cervical carcinoma. Mol Clin Oncol. 2018;2(9):138–44. https://doi.org/10.3892/mco.2018.1646.
14.  Yu Y, Wen X, Lin Y, Zhang X, Chen Y, Wang W, et al. The value of preoperative Glasgow prognostic score and the C-reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. J Cancer. 2018;9(5):807–15. https://doi.org/10.7150/jca.22755.
15.  Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, et al. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric. 2018. https://doi.org/10.1016/j.tjgo.2018.05.028.
16.  Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z, et al. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015;113(4):626–33. https://doi.org/10.1038/bjc.2015.241.
17.  Tomita M, Ayabe T, Maeda R, Nakamura K. Comparison of inflammation-based prognostic scores in patients undergoing curative resection for non-small cell lung cancer. World J Oncol. 2018;9(3):85–90. https://doi.org/10.1014/j.740/wpj:oaj1097w.
18.  Zheng RR, Huang M, Jin C, Wang HC, Yu JT, Zeng LC, et al. Cervical cancer systemic inflammation score: a novel predictor of prognosis. Oncotarget. 2016;7(12):15230–42. https://doi.org/10.18632/oncotarget.7378.
19.  Han L, Song Q, Jia Y, Chen X, Wang C, Chen P, et al. The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma. Tumour Biol. 2016;37(2):3081–90. https://doi.org/10.1007/s13277-015-4152-1.
20.  Laviano A, Di Lazzaro L, Koverech A. Nutrition support and clinical outcome in advanced cancer patients. Proc Nutr Soc. 2017;77(4):388–93. https://doi.org/10.1017/s0002665118000459.
21.  Gupta D, Liu CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. https://doi.org/10.1186/1475-2891-9-69.
22. Hu G, Liu G, Ma JY, Hu RJ. Lymphocyte-to-monocyte ratio in esophageal squamous cell carcinoma prognosis. Clin Chim Acta. 2018;486:44-8. https://doi.org/10.1016/j.cca.2018.07.029.

23. Suh B, Park S, Shin DW, Yun JM, Keam B, Yang HK, et al. Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults. Ann Oncol. 2014;25(11):2260-6. https://doi.org/10.1093/annonc/mdu274.

24. Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and clinical outcomes: what is the mechanism behind the relationship? Am Surg. 2017;83(11):1220-7.

25. Fang P, Jiang W, Davuluri R, Xu C, Krishnan S, Mohan R, et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol. 2018;128(3):584-90. https://doi.org/10.1016/j.radonc.2018.02.025.

26. Duan H, Zhang X, Wang FX, Cai MY, Ma GW, Yang H, et al. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma. World J Gastroenterol. 2015;21(18):5591-7. https://doi.org/10.3748/wjg.v21.i18.5591.

27. Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M, et al. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients. Surg Today. 2016;46(4):405-13. https://doi.org/10.1007/s00595-015-1197-0.

28. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36(3):617-22. https://doi.org/10.1007/s00268-011-1411-1.

29. Deng J, Zhang P, Sun Y, Peng P, Huang Y. Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis. J Thorac Dis. 2018;10(3):1522-31. https://doi.org/10.21037/jtd.2018.02.58.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.